18. Non-Hodgkin Lymphomas

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Nathan Fowler and
  2. Peter McLaughlin

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch18

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Fowler, N. and McLaughlin, P. (2011) Non-Hodgkin Lymphomas, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch18

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016

SEARCH

Keywords:

  • Non-Hodgkin lymphoma;
  • B-cell;
  • T-cell;
  • follicular;
  • MALT;
  • mantle cell;
  • monoclonal antibody;
  • stem cell transplant;
  • biologic therapy;
  • late effects

Summary

The non-Hodgkin lymphomas (NHL) are a diverse group of neoplasms. Classification is based on morphology, phenotype (e.g., B- vs. T-cell), and ancillary factors that can include clinical presentation, cytogenetics and, sometimes, molecular genetic features. Most patients present with symptoms secondary to nodal growth or bone marrow involvement. The clinical presentation and natural history often varies depending on the subtype of NHL. Radiation alone, and in combination with chemotherapy, has been used successfully in localized disease. Management of extensive stage disease typically involves a systemic chemotherapy approach with combinations of multiple non-cross-resistant agents. In relapsed lymphoma, stem cell transplant has been shown to improve survival in some patients. Monoclonal antibodies and other biologic agents have demonstrated exciting activity and are taking a larger role in newer chemotherapy regimens. Late effects of therapy are a concern; it is hoped that newer targeted and biological therapy approaches may minimize these risks.